Director Henry O. Gosebruch filed a Form 4 with the SEC on August 27, 2026, disclosing the acquisition of 6,662 shares of ANI Pharmaceuticals Inc common stock on August 19, 2026, in the form of a restricted stock award at no cost.

Key Highlights

  • Reporting person: Henry O. Gosebruch, a Director of ANI Pharmaceuticals Inc (NASDAQ:ANIP)
  • Transaction date: August 19, 2026
  • Shares acquired: 6,662 shares of common stock, transaction code A (acquired)
  • Price paid: $0 per share
  • Post-transaction ownership: 6,662 shares held directly
  • Vesting schedule: Three equal annual installments on the first, second, and third anniversaries of August 19, 2026

Henry O. Gosebruch Restricted Stock Award Details

According to the filing, Henry O. Gosebruch, serving as a Director of ANI Pharmaceuticals Inc, received a restricted stock award of 6,662 shares of common stock on August 19, 2026, at a price of $0. The transaction is recorded under transaction code A, indicating an acquisition. Following this transaction, the filing reports that Gosebruch directly owns 6,662 shares of ANI Pharmaceuticals common stock, representing his entire reported beneficial ownership position in the company at the time of filing.

The filing's footnote explains that the award "will vest in three equal annual installments on the first, second and third anniversaries of August 19, 2026." No derivative securities were reported in Table II of the filing. The Form 4 was signed by Meredith W. Cook as attorney-in-fact for Henry O. Gosebruch and filed with the SEC on August 27, 2026. No indication is given in the filing that the transaction was made pursuant to a Rule 10b5-1 plan.

What Was Disclosed

The filing discloses that ANI Pharmaceuticals Director Henry O. Gosebruch received a restricted stock award of 6,662 shares of common stock on August 19, 2026, at no cost, with vesting in three equal annual installments beginning on the first anniversary of the grant date.